Core Viewpoint - Qingdao Haier Biomedical Co., Ltd. announced that its actual controller's concerted action party, Haichuangzhi, has completed a share buyback plan, acquiring 5,729,305 shares, which is 1.8% of the total share capital, for a total amount of 181.84 million yuan [2][8]. Group 1 - The share buyback plan was initiated on January 8, 2025, with a target to purchase between 100 million yuan and 200 million yuan within six months [2][6]. - As of April 10, 2025, Haichuangzhi has completed the buyback, with an average purchase price of 31.74 yuan per share [7][8]. - Following the buyback, Haichuangzhi holds 8,675,900 shares, representing 2.73% of the total share capital, while Haier Group and its concerted action parties collectively hold 141,371,022 shares, or 44.46% of the total [8]. Group 2 - The purpose of the buyback is to enhance investor confidence based on the belief in the company's future development and long-term investment value [4]. - The buyback was executed through a centralized bidding method on the Shanghai Stock Exchange [7]. - The buyback plan did not set a price range and was subject to market conditions [7].

当前，AI与医疗健康的融合已从技术探索迈向规模化应用，推动行业进入数智化转型新阶段。4月8日-11日， 在 第91届中国国际医疗器械(春季)博览会 (以下简称"CMEF") 上，盈康一生旗下 海尔生物医疗 以"Ai在海 尔，因Ai盈康 "为主题，携多个"AI+智慧场景"和15大明星产品重磅亮相。 从AI+智慧样本库、AI+智慧科研，到AI+智慧用药、AI+智慧疫苗接种、AI+智慧血液管理，海尔生物医疗以新 科技、新场景、新生态，不仅为行业带来一场生命科学与医疗创新+AI的生态成果盛宴，也为产业重构带来了 未来想象空间。 # 逐"绿"向"智"，构建生命科学研究新范式 在可持续发展与智能化转型浪潮下，绿色科技与AI技术正重构生命科学产业范式，加速推进全链条数智化进 程。此次CMEF上，海尔生物医疗立足 样本高质量保藏管理和医院临床干细胞研究 ，为高校、科研机构、医 院、药企等用户带来了 一站式样本库全生命周期解决方案、可按需定制的智慧实验室场景解决方案 等，助力 生命科学研究和前沿医学进步。 在AI+智慧样本库展区，海尔生物医疗立足高质量样本库建设需求，带来了 一站式样本库全生命周期解决方案 和4大首发新品。 基 ...

Group 1: Core Insights - The report discusses the impact of Trump's tariffs and countermeasures on various industries, highlighting the need for a trading mindset in consumer stocks [3] - It notes significant fluctuations in global asset prices due to trade uncertainties, with a focus on the quantitative monitoring of trade uncertainty and global panic trading levels [4] Group 2: Industry Performance - The shipping industry is directly affected by the tariffs, with a notable increase in container shipping volume from Asia to North America during the 2018 trade war, which saw a 6.63% year-on-year increase and a 175.77% rise in freight rates [5] - The report indicates that the shipping demand on the US route is exposed to high tariff risks, with no buffer period for the implementation of counter-tariffs, leading to a decline in export demand and potential impacts on shipping schedules and port efficiency [8] Group 3: Company Analysis - China Energy Construction (601868.SH) shows steady revenue growth with a significant expansion in new energy installations, projecting net profits of 9.3 billion, 10 billion, and 10.5 billion for 2025-2027, with respective growth rates of 10%, 8%, and 5% [10] - Haier Biomedical (688139.SH) reported a slight revenue increase of 0.13% in 2024, with a net profit of 367 million, although it experienced a decline of 9.71% year-on-year; however, the company is expected to see a recovery in 2025 with projected revenues of 2.623 billion, 3.023 billion, and 3.479 billion for 2025-2027, reflecting growth rates of 14.9%, 15.2%, and 15.1% respectively [11][12]

导读： 4月7日，A股清明节假期后开盘。早盘，三大股指全线低开，沪指低开4.46%，深指低开5.96%，创业板指低开6.77%。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 4月7日，A股清明节假期后开盘。早盘，三大股指全线低开，沪指低开4 . 4 6%，深指低开5 . 9 6%，创业板指低开 6 . 7 7%。 不只是A股。4月7日早盘，亚太市场的日韩股市开盘均现大跌，日经2 2 5指数盘中跌幅超8%，韩国股指大跌近5%。韩 国交易所在KOSPI 2 0 0指数期货下跌5%后，启动了KOSPI的si d e c a r停牌机制，并暂停程序化交易5分钟。此外，中国 台湾证交所股票交易触发熔断，熔断前台湾加权指数跌9 . 7%。港股方面，恒生指数开盘跌9 . 2 8%，恒生科技指数跌 11 . 1 5%，恒生中国企业指数跌9 . 0 7%。 | 大盘指数 | | 申示) | | --- | --- | --- | | 名称 | 最新 | 幅度 | | 上证指数 1A0001 | 3193.10 | -4.46% | | 深证成指 ...

Macro Strategy - The core impact of the recent reciprocal tariffs is on the existing global tariff and trade system rather than solely on China's exports, with the overall tariff rate on Chinese imports reaching 64.66% [18][19] - The new tariffs may lead to a GDP growth drag of approximately 1.5% for China, with a potential 31.5% decline in exports to the US [19] Fixed Income Analysis - The analysis indicates that the adjusted yield of bank assets can signal interest rate turning points, specifically when the adjusted yield of 3M interbank certificates rises to the level of corporate loan yields, indicating a potential downward turning point for interest rates [20][21] - The report highlights the importance of comparing yields between different asset classes to predict market movements [20] Industry Insights - In the engineering machinery sector, the direct export cost burden due to tariffs has increased to 79%, but the overall exposure to the US market is manageable for major players like SANY and XCMG, with their US exposure being relatively low [24] - Companies with manufacturing facilities in North America or Mexico are better positioned to mitigate tariff risks, with SANY and Hengli Hydraulic being notable examples [24]

Core Viewpoint - The company reported its 2024 annual results, showing a slight revenue increase but a decline in net profit, with expectations for significant growth in overseas markets in 2025 [1][2]. Financial Performance - In 2024, the company achieved revenue of 2.28 billion yuan (+0.1%) and a net profit attributable to shareholders of 367 million yuan (-9.7%), with a non-recurring net profit of 321 million yuan (-2.9%) [1]. - Quarterly revenue for 2024 was 690 million yuan in Q1, 540 million yuan in Q2, 560 million yuan in Q3, and 500 million yuan in Q4, showing a quarterly growth of +0%, -8.1%, +0.5%, and +10.4% respectively [1]. - Quarterly net profit attributable to shareholders was 140 million yuan in Q1, 97 million yuan in Q2, 75 million yuan in Q3, and 57 million yuan in Q4, with changes of +0.1%, -31.4%, -5%, and +17.6% respectively [1]. Business Segments - The storage segment experienced negative growth, but excluding the solar vaccine cold storage, it remained flat; non-storage revenue grew by 21% [1]. - The low-temperature storage business faced challenges but showed improvement, with the decline primarily due to delays in solar vaccine orders. The second half of the year saw a narrowing decline, achieving positive growth in Q4 [2]. - Non-low-temperature storage equipment, including automated medication, laboratory consumables, and digital public health, continued to grow rapidly [2]. Market Expansion - The company is deepening its global presence, with overseas markets (excluding solar vaccine solutions) achieving double-digit growth. The company has established localized teams in key countries such as the USA, UK, Netherlands, Singapore, and India [2]. - The company has received local certification for 56 new product models, totaling over 400 overseas product certifications, and is accelerating local construction to shorten product delivery cycles [2]. Profit Forecast - The company forecasts net profit attributable to shareholders of 440 million yuan in 2025, 520 million yuan in 2026, and 600 million yuan in 2027, indicating steady growth and potential for future acquisitions [3].

Group 1: Core Views - The valuation of Chinese technology assets has rapidly recovered and then retreated, with the Hang Seng Technology Index reaching a peak increase of 39% this year [1] - The narrative around the rise of AI in China has become a consensus, shifting investor focus to earnings expectations, CAPEX growth, and the efficiency improvements brought by AI applications [1] - The company maintains an optimistic outlook for Chinese technology assets, anticipating technical advancements and application implementations to drive upward revisions in earnings forecasts [1] Group 2: Investment Opportunities and Risks - The Hang Seng Technology Index may enter a short-term consolidation phase after a rapid valuation increase, with potential upward drivers including advancements from major model vendors and strong earnings guidance from leading internet and cloud companies [1] - The valuation increase in the Hang Seng Technology Index may spill over into investment opportunities in innovative pharmaceuticals and AI+ healthcare sectors [1] - The recent decline in the Hang Seng Technology Index presents a mid-term buying opportunity [1] Group 3: Market Dynamics - The Hong Kong stock market has experienced a decline of 11.6% since March 19 due to factors such as stock placements and impending "reciprocal tariffs," but the overall reversal trend for the year remains intact [3] - Historical peaks in stock placements typically occur during periods of ample liquidity and relatively high valuations, suggesting that current market conditions may support stock prices in the medium to long term [3] - The dynamic PE ratios for the Hang Seng Index and Hang Seng Technology Index are currently at 10.3x and 17.5x, respectively, indicating significant value compared to historical levels [3] Group 4: Sector Performance - The healthcare sector is expected to show signs of demand or performance recovery in Q1 2025, driven by policy optimization and AI empowerment, leading to a valuation reassessment [8] - The computer industry is projected to see steady revenue growth in Q1 2025, with particular strength in computing power, AI applications, and related sectors [10] - The agricultural chemicals sector is focusing on global expansion to counteract domestic pressures, with leading companies leveraging their integrated supply chains to enhance overseas market share [15]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The pharmaceutical sector showed signs of recovery with a slight outperformance against the Shanghai and Shenzhen 300 Index, with the Shenwan Pharmaceutical Bio Index rising by 0.98% from March 24 to March 28, 2025, ranking first among 31 Shenwan primary industry indices [2][12]. - Year-to-date, the Shenwan Pharmaceutical Bio Index has increased by 3.53%, outperforming the Shanghai and Shenzhen 300 Index by 4.03 percentage points, ranking 12th among the 31 indices [2][14]. - As of March 28, 2025, the valuation of the pharmaceutical sector stands at 26.72 times (TTM overall method, excluding negative values), with a premium of 139.55% compared to the Shanghai and Shenzhen 300 Index [2][15]. Summary by Sections 1. Weekly Market Review - The pharmaceutical sector outperformed the Shanghai and Shenzhen 300 Index, with a weekly increase of 0.98% [2][12]. - The sector's valuation is at 26.72 times, reflecting a significant premium over the broader market [15]. 2. Important Policies and Events - On March 26, 2025, the National Healthcare Security Administration held a meeting to optimize drug procurement policies, releasing a draft proposal that includes six key areas for improvement, such as optimizing procurement varieties and standards, enhancing quality assessment, and increasing transparency [4][21]. 3. Important Company Announcements - Boteng Co., Ltd. reported a revenue of 3.012 billion yuan for 2024, a year-on-year decrease of 17.87%, with a net profit of -288 million yuan, down 207.83% [22]. - Haier Biomedical reported a revenue of 2.283 billion yuan for 2024, a slight increase of 0.13%, with a net profit of 367 million yuan, down 9.71% [22]. 4. Industry Perspectives - The ongoing drug procurement policies have led to significant price reductions for winning bids, impacting company performance and investor confidence. The recent draft proposal aims to adjust the procurement mechanism to prevent low-price bidding and ensure stable supply [5][23][24]. - The adjustments in the procurement rules are expected to restore investor confidence in hospital medication, with potential recovery for quality generic drug companies [5][24].

Core Viewpoint - The company focuses on providing integrated digital solutions in the life sciences and medical innovation sectors, leveraging advanced technologies to enhance user experience and drive industry transformation [5][6][25]. Company Overview - The company operates in two main segments: life sciences and medical innovation, offering solutions such as smart laboratories and digital hospitals [5]. - The company has established a strong global presence, with products and solutions applied in over 150 countries and regions [6][26]. Business Model - The company maintains a comprehensive control over the entire process from research and development to sales and after-sales service [7]. - The procurement process involves rigorous supplier qualification and just-in-time inventory management [8]. Industry Situation - The life sciences and medical innovation sectors are experiencing growth driven by increased demand for integrated solutions and advancements in technology [12][21]. - The global life sciences tools market is projected to reach $330.69 billion by 2030, with significant growth in the Asia-Pacific region [12]. Technological Advancements - The company has developed six major technology platforms and holds 1,595 patents, positioning itself as a leader in biomedicine and low-temperature technology [25]. - The integration of IoT, cloud computing, and AI into the company's offerings is expected to enhance operational efficiency and user experience [27][28]. Financial Highlights - The company plans to distribute a cash dividend of 4.7 yuan per 10 shares, totaling approximately 147.8 million yuan [3]. Future Development Trends - The industry is shifting towards automation and intelligent solutions, with a focus on enhancing operational efficiency and reducing costs [28][29]. - The company aims to capitalize on the growing demand for digital solutions in healthcare, driven by national policies and technological advancements [17][19][31].

Company Overview - Haier Biomedical focuses on the research, production, and sales of biomedical low-temperature storage equipment, providing digital scene solutions in life sciences and medical innovation [2] - The company serves a wide range of users, including hospitals, biopharmaceutical companies, research institutions, disease control centers, and blood stations, offering comprehensive solutions centered around smart laboratories and digital hospitals [2] - Haier Biomedical has established partnerships with over 40 international organizations, including WHO and UNICEF, and its products are applied in more than 130 countries and regions globally [2] Financial Performance - As of the latest quarterly report for 2024, the company achieved a revenue of 1.782 billion yuan, a year-on-year decrease of 2.43%, and a net profit of 309 million yuan, down 13.45% year-on-year, with a gross profit margin of 48.51% [2] - The company's stock closed at 33.78 yuan, with a rolling price-to-earnings (PE) ratio of 29.29 times and a total market capitalization of 10.740 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 44.91 times, with a median of 31.89 times, positioning Haier Biomedical at the 69th rank within the industry [1][3] - The company has a lower PE ratio compared to the industry average, indicating potential undervaluation relative to its peers [3] Shareholder Information - As of September 30, 2024, Haier Biomedical had 12,200 shareholders, an increase of 1,510 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]